Pharmacologic abrogation of the mitotic spindle checkpoint by an indolocarbazole discovered by cellular screening efficiently kills cancer cells

Cancer Research

Volumn 69, Issue 9, 2009, Pages 3874-3883

  Stolz, Ailine ^a   Vogel, Celia ^a   Schneider, Verena ^a   Ertych, Norman ^a   Kienitz, Anne ^a   Yu, Hongtao ^b   Bastians, Holger ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 [8 [(DIMETHYLAMINO)METHYL] 6,7,8,9 TETRAHYDROPYRIDO[1,2 A]INDOL 10 YL] 4 (1 METHYL 1H INDOL 3 YL) 1H PYRROLE 2,5 DIONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 7 HYDROXYSTAUROSPORINE; AURORA A KINASE; AURORA B KINASE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; MONASTROL; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; NOCODAZOLE; PACLITAXEL; RO31 8220; RO32 0432; ROSCOVITINE; ROTTLERIN; SORAFENIB; STAUROSPORINE; UNCLASSIFIED DRUG;

ANAPHASE; ANEUPLOIDY; APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE PHASE; CELL CYCLE PROGRESSION; CELL LINE; CELL SCREENING; CELL VIABILITY; CENTROMERE; CHROMOSOME; FLOW CYTOMETRY; HUMAN; HUMAN CELL; METAPHASE; MITOSIS SPINDLE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SISTER CHROMATID; WESTERN BLOTTING;

APOPTOSIS; CARBAZOLES; CHROMOSOME ABERRATIONS; COLONIC NEOPLASMS; DRUG SYNERGISM; ENZYME INHIBITORS; HCT116 CELLS; HUMANS; MITOSIS; MITOTIC SPINDLE APPARATUS; NOCODAZOLE; PACLITAXEL; PROTEIN-SERINE-THREONINE KINASES;

EID: 65949089639     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3597     Document Type: Article

References (44)

1. Schmidt M, Bastians H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Updat 2007; 10: 162-81.
2. Bharadwaj R, Yu H. The spindle checkpoint, aneuploidy, and cancer. Oncogene 2004; 23: 2016-27.
3. Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 2007; 8: 379-93.
4. Rieder CL, Maiato H. Stuck in division or passing through:what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 2004; 7: 637-51.
5. Brito DA, Rieder CL. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol 2006; 16: 1194-200.
6. Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008; 14: 111-22.
7. Kim M, Liao J, Dowling ML, et al. TRAIL inactivates the mitotic checkpoint and potentiates death induced by microtubule-targeting agents in human cancer cells. Cancer Res 2008; 68: 3440-9.
8. Tao W, South VJ, Zhang Y, et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 2005; 8: 49-59.
9. Sudo T, Nitta M, Saya H, Ueno NT. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 2004; 64: 2502-8.
10. Masuda A, Maeno K, Nakagawa T, Saito H, Takahashi T. Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. Am J Pathol 2003; 163: 1109-16.
11. Kienitz A, Vogel C, Morales I, Muller R, Bastians H. Partial downregulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol. Oncogene 2005; 24: 4301-10.
12. Kasai T, Iwanaga Y, Iha H, Jeang KT. Prevalent loss of mitotic spindle checkpoint in adult T-cell leukemia confers resistance to microtubule inhibitors. J Biol Chem 2002; 277: 5187-93.
13. Swanton C, Marani M, Pardo O, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007; 11: 498-512.
14. Allan LA, Clarke PR. Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis. Mol Cell 2007; 26: 301-10.
15. Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003; 3: 51-62.
16. Vader G, Maia AF, Lens SM. The chromosomal passenger complex and the spindle assembly checkpoint:kinetochore-microtubule error correction and beyond. Cell Div 2008; 3: 10.
17. Ruchaud S, Carmena M, Earnshaw WC. Chromosomal passengers:conducting cell division. Nat Rev Mol Cell Biol 2007; 8: 798-812.
18. Wang X, Jin DY, Ng RW, et al. Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells. Cancer Res 2002; 62: 1662-8.
19. Hernando E, Nahle Z, Juan G, et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 2004; 430: 797-802.
20. Sotillo R, Hernando E, Diaz-Rodriguez E, et al. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 2007; 11: 9-23.
21. Guardavaccaro D, Frescas D, Dorrello NV, et al. Control of chromosome stability by the β-TrCP-REST- Mad2 axis. Nature 2008; 452: 365-9.
22. Perez de Castro I, de Carcer G, Malumbres M. A census of mitotic cancer genes:new insights into tumor cell biology and cancer therapy. Carcinogenesis 2007; 28: 899-912.
23. Cahill DP, Lengauer C, Yu J, et al. Mutations of mitotic checkpoint genes in human cancers. Nature 1998; 392: 300-3.
24. Saeki A, Tamura S, Ito N, et al. Frequent impairment of the spindle assembly checkpoint in hepatocellular carcinoma. Cancer 2002; 94: 2047-54.
25. Yoon DS, Wersto RP, Zhou W, et al. Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer. Am J Pathol 2002; 161: 391-7.
26. Takahashi T, Haruki N, Nomoto S, et al. Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes, hsMAD2 and p55CDC, in human lung cancers. Oncogene 1999; 18: 4295-300.
27. Weaver BA, Cleveland DW. Does aneuploidy cause cancer? Curr Opin Cell Biol 2006; 18: 658-67.
28. Shichiri M, Yoshinaga K, Hisatomi H, Sugihara K, Hirata Y. Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. Cancer Res 2002; 62: 13-7.
29. Ricke RM, van Ree JH, van Deursen JM. Whole chromosome instability and cancer:a complex relationship. Trends Genet 2008; 24: 457-66.
30. Dobles M, Liberal V, Scott ML, Benezra R, Sorger PK. Chromosome missegregation and apoptosis in mice lacking the mitotic checkpoint protein Mad2. Cell 2000; 101: 635-45.
31. Kalitsis P, Earle E, Fowler KJ, Choo KH. Bub3 gene disruption in mice reveals essential mitotic spindle checkpoint function during early embryogenesis. Genes Dev 2000; 14: 2277-82.
32. Michel L, Diaz-Rodriguez E, Narayan G, Hernando E, Murty VV, Benezra R. Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc Natl Acad Sci U S A 2004; 101: 4459-64.
33. Kops GJ, Foltz DR, Cleveland DW. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci U S A 2004; 101: 8699-704.
34. Tang Z, Shu H, Oncel D, Chen S, Yu H. Phosphorylation of Cdc20 by Bub1 provides a catalytic mechanism for APC/C inhibition by the spindle checkpoint. Mol Cell 2004; 16: 387-97.
35. Vogel C, Kienitz A, Hofmann I, Muller R, Bastians H. Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy. Oncogene 2004; 23: 6845-53.
36. Ditchfield C, Johnson VL, Tighe A, et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 2003; 161: 267-80.
37. Lee EA, Keutmann MK, Dowling ML, Harris E, Chan G, Kao GD. Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol Cancer Ther 2004; 3: 661-9.
38. Vogel C, Kienitz A, Muller R, Bastians H. The mitotic spindle checkpoint is a critical determinant for topoisomerase-based chemotherapy. J Biol Chem 2005; 280: 4025-8.
39. Vogel C, Hager C, Bastians H. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Res 2007; 67: 339-45.
40. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 253-65.
41. Keen N, Taylor SS. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004; 4: 927-36.
42. Marumoto T, Zhang D, Saya H. Aurora-A-a guardian of poles. Nat Rev Cancer 2005; 5: 42-50.
43. Hauf S, Cole RW, LaTerra S, et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 2003; 161: 281-94.
44. Schmidt M, Budirahardja Y, Klompmaker R, Medema RH. Ablation of the spindle assembly checkpoint by a compound targeting Mps1. EMBO Rep 2005; 6: 866-72.